[{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"09e74a0b-2911-4165-9b8f-e77d19ed6b2f","acronym":"TroFuse-004","url":"https://clinicaltrials.gov/study/NCT06074588","created_at":"2023-10-10T14:11:53.919Z","updated_at":"2025-02-25T13:49:58.239Z","phase":"Phase 3","brief_title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","source_id_and_acronym":"NCT06074588 - TroFuse-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 556","initiation":"Initiation: 11/12/2023","start_date":" 11/12/2023","primary_txt":" Primary completion: 05/10/2027","primary_completion_date":" 05/10/2027","study_txt":" Completion: 03/11/2030","study_completion_date":" 03/11/2030","last_update_posted":"2025-02-20"},{"id":"258815b3-da9e-48e7-8a38-615cfaef4dbd","acronym":"TROPION-Lung02","url":"https://clinicaltrials.gov/study/NCT04526691","created_at":"2021-01-18T21:40:42.295Z","updated_at":"2025-02-25T14:07:50.610Z","phase":"Phase 1","brief_title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","source_id_and_acronym":"NCT04526691 - TROPION-Lung02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-02-19"},{"id":"9e22f735-9f0d-4c3a-92fb-91f43ae1a4bd","acronym":"TROPION-LUNG01","url":"https://clinicaltrials.gov/study/NCT04656652","created_at":"2021-01-19T20:41:43.327Z","updated_at":"2025-02-25T14:59:32.426Z","phase":"Phase 3","brief_title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","source_id_and_acronym":"NCT04656652 - TROPION-LUNG01","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 06/21/2025","study_completion_date":" 06/21/2025","last_update_posted":"2025-02-13"},{"id":"6443d84d-18f2-435e-a44c-d58932c7c829","acronym":"SKB264-II-04","url":"https://clinicaltrials.gov/study/NCT05816252","created_at":"2023-04-18T15:04:37.057Z","updated_at":"2025-02-25T15:20:25.216Z","phase":"Phase 2","brief_title":"A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05816252 - SKB264-II-04","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-02-12"},{"id":"a5c52f3d-d931-4d6c-a0fc-d7a329637aae","acronym":"ADAPT-TN-III","url":"https://clinicaltrials.gov/study/NCT06081244","created_at":"2023-10-14T01:13:01.938Z","updated_at":"2025-02-25T15:20:56.304Z","phase":"Phase 2","brief_title":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","source_id_and_acronym":"NCT06081244 - ADAPT-TN-III","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 10/10/2024","start_date":" 10/10/2024","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-02-12"},{"id":"6d363f74-eebb-42b8-8282-8889b9922b4e","acronym":"TROPION-Breast04","url":"https://clinicaltrials.gov/study/NCT06112379","created_at":"2023-11-01T15:12:45.942Z","updated_at":"2025-02-25T16:40:21.913Z","phase":"Phase 3","brief_title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","source_id_and_acronym":"NCT06112379 - TROPION-Breast04","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 1728","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 03/29/2028","primary_completion_date":" 03/29/2028","study_txt":" Completion: 08/28/2030","study_completion_date":" 08/28/2030","last_update_posted":"2025-02-06"},{"id":"469953ef-24ff-4f0d-8592-38f0c64f71f3","acronym":"TROPION-Lung04","url":"https://clinicaltrials.gov/study/NCT04612751","created_at":"2021-01-19T20:32:55.031Z","updated_at":"2025-02-25T16:45:13.114Z","phase":"Phase 1","brief_title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04612751 - TROPION-Lung04","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-05"},{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"fd07330d-4021-4953-a335-77bf14292062","acronym":"ASCENT-05","url":"https://clinicaltrials.gov/study/NCT05633654","created_at":"2022-12-01T15:57:14.884Z","updated_at":"2025-02-25T17:31:43.714Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)","source_id_and_acronym":"NCT05633654 - ASCENT-05","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • capecitabine • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 1514","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 08/01/2031","study_completion_date":" 08/01/2031","last_update_posted":"2025-01-30"},{"id":"e0140ec6-c75d-43bd-8e7c-53aed0cb1b56","acronym":"WIN-B","url":"https://clinicaltrials.gov/study/NCT06612203","created_at":"2025-02-25T18:45:57.055Z","updated_at":"2025-02-25T18:45:57.055Z","phase":"Phase 1/2","brief_title":"Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06612203 - WIN-B","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • zedoresertib (Debio 0123)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 01/17/2025","start_date":" 01/17/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-24"},{"id":"de2401e1-5d7d-4d66-a7ff-49b260d21b77","acronym":"ASCENT-04","url":"https://clinicaltrials.gov/study/NCT05382286","created_at":"2022-05-19T11:56:14.579Z","updated_at":"2025-02-25T16:17:43.197Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05382286 - ASCENT-04","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 443","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-12-24"},{"id":"ef68472b-7dd2-408d-a78b-45ffa120bc34","acronym":"Tropion-Lung08","url":"https://clinicaltrials.gov/study/NCT05215340","created_at":"2022-02-05T18:27:45.512Z","updated_at":"2025-02-25T15:00:14.693Z","phase":"Phase 3","brief_title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05215340 - Tropion-Lung08","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 740","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-12-13"},{"id":"84d273e3-f912-4f66-80af-054c9469875c","acronym":"TROPION-PanTumor01","url":"https://clinicaltrials.gov/study/NCT03401385","created_at":"2021-01-18T16:47:07.204Z","updated_at":"2025-02-25T14:58:37.689Z","phase":"Phase 1","brief_title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","source_id_and_acronym":"NCT03401385 - TROPION-PanTumor01","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-03"},{"id":"b0b8fd2c-45d2-439d-baa9-7ef0bc159fed","acronym":"TROPION-Lung07","url":"https://clinicaltrials.gov/study/NCT05555732","created_at":"2022-09-27T14:04:32.746Z","updated_at":"2025-02-25T15:00:38.318Z","phase":"Phase 3","brief_title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","source_id_and_acronym":"NCT05555732 - TROPION-Lung07","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 1170","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-11-12"},{"id":"0983518d-a48f-44db-87f7-0f334b50208a","acronym":"Saci-IO TNBC","url":"https://clinicaltrials.gov/study/NCT04468061","created_at":"2021-01-18T21:28:18.947Z","updated_at":"2025-02-25T16:10:30.435Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","source_id_and_acronym":"NCT04468061 - Saci-IO TNBC","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-09-19"},{"id":"50d017e4-c038-44db-850c-687452cadcfc","acronym":"Saci-IO HR+","url":"https://clinicaltrials.gov/study/NCT04448886","created_at":"2021-01-18T21:24:20.750Z","updated_at":"2025-02-25T16:10:28.010Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC","source_id_and_acronym":"NCT04448886 - Saci-IO HR+","lead_sponsor":"Ana C Garrido-Castro, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 03/09/2024","primary_completion_date":" 03/09/2024","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-10"},{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"1c9daf03-acbe-412b-99d6-f63aac6d1d20","acronym":"EVER-132-002","url":"https://clinicaltrials.gov/study/NCT04639986","created_at":"2021-01-19T20:38:27.058Z","updated_at":"2024-07-02T16:34:26.121Z","phase":"Phase 3","brief_title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT04639986 - EVER-132-002","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"5f860286-e6e3-44bc-a0d0-5065d0478838","acronym":"ASCENT-03","url":"https://clinicaltrials.gov/study/NCT05382299","created_at":"2022-05-19T11:56:14.957Z","updated_at":"2024-07-02T16:34:26.679Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05382299 - ASCENT-03","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-06-12"},{"id":"594eece6-f64f-4da2-846a-6e75f33b175c","acronym":"EVOKE-01","url":"https://clinicaltrials.gov/study/NCT05089734","created_at":"2021-10-22T12:53:05.373Z","updated_at":"2024-07-02T16:34:59.762Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05089734 - EVOKE-01","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 11/17/2021","start_date":" 11/17/2021","primary_txt":" Primary completion: 11/29/2023","primary_completion_date":" 11/29/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-31"}]